Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences MetaboMeeting 2015

James R Armitage's Biography

James R Armitage, Senior Scientist, GSK

Having studied Biomedical Science at university, I worked briefly at AgrEvo, investigating agrochemical ADME and bioavailability. In 2000, I was afforded the opportunity to join Investigative Pre-Clinical Safety at SmithKline Beecham to develop predictive proteomic models of preclinical toxicity. Following the formation of GSK, I have continued to work within Investigative Safety Assessment until the present day. During this time I have the opportunity to expand into metabolomic/biochemical based safety assessment and toxicity prediction. In the last 5 years, I have had the good fortune (initially on secondment and now permanently) to work in a amazing group focussed on mitochondrial toxicity. In the Mitochondrial Group I head up work using metabolomics to develop in-vivo markers and measures of mitochondrial dysfunction that can routinely be applied to studies as NCEs pass through safety assessment.

James R Armitage Image

Mitochondrial Metabolomics: Identifying Early in-vivo Biochemical Markers of Mitochondrial Toxicity

Wednesday, 9 December 2015 at 10:00

Add to Calendar ▼2015-12-09 10:00:002015-12-09 11:00:00Europe/LondonMitochondrial Metabolomics: Identifying Early in-vivo Biochemical Markers of Mitochondrial ToxicityMetaboMeeting 2015 in Cambridge, UKCambridge,

There are no easily accessible biomarkers to monitor compound-mediated effects on mitochondria in-vivo. A known mitochondrial toxin was employed to identify metabolites that change in advance or absence of a clinical effect to identify sensitive in-vivo indicators of mitochondrial function.

Add to Calendar ▼2015-12-07 00:00:002015-12-09 00:00:00Europe/LondonMetaboMeeting 2015MetaboMeeting 2015 in Cambridge, UKCambridge,